TipRanks
PharmaCyte Biotech (DE:EFYA)
STUTTGART:EFYA
Germany Market
EFYA
PharmaCyte Biotech
RESEARCH TOOLSreports

PharmaCyte Biotech (EFYA) Income Statement

2 Followers

PharmaCyte Biotech Income Statement

Last quarter (Q1 2027), PharmaCyte Biotech's total revenue was $0.00, a decrease of ― from the same quarter last year. In Q1, PharmaCyte Biotech's net income was $-5.79M. See PharmaCyte Biotech’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Apr 26Apr 25Apr 24Apr 23Apr 22
Total Revenue
$ 0.00$ 0.00$ 0.00$ 0.00$ 0.00
Gross Profit
$ 0.00$ 0.00$ 0.00$ 0.00$ 0.00
Operating Expenses
$ 6.85M$ 4.38M$ 8.52M$ 6.46M$ 4.39M
Depreciation and Amortization
$ 0.00$ 0.00$ 0.00$ 0.00$ 0.00
EBITDA
$ -5.30M$ -4.38M$ -6.52M$ -6.46M$ -4.24M
Operating Income
$ -6.85M$ -4.38M$ -8.52M$ -6.46M$ -4.39M
Other Income/Expenses
$ -12.57M$ 35.03M$ 8.85M$ 2.14M$ 152.85K
Pretax Income
$ -19.42M$ 30.66M$ 333.76K$ -4.32M$ -4.24M
Net Income
$ -19.42M$ 30.66M$ 333.76K$ -4.32M$ -4.24M
Per Share Metrics
Basic EPS
$ -2.77$ 3.19$ -1.80$ -0.22$ -0.27
Diluted EPS
$ -2.77$ 3.19$ -1.80$ -0.22$ -0.27
Weighted Average Shares Outstanding
 7.01M 7.33M 185.00K 19.49M 15.52M
Weighted Average Shares Outstanding (Diluted)
 8.38M 7.33M 9.58M 19.49M 15.52M
Currency in USD

PharmaCyte Biotech Earnings and Revenue History